Nov 15, 2023 / 06:30PM GMT
Peter James Welford - Jefferies LLC, Research Division - Senior Equity Analyst & European Pharmaceuticals Analyst
Okay. Thank you very much, QIAGEN. We've got here. We have Roland Sackers, the CFO; and we have John Gilardi from Investor Relations joining me on the front here. Perhaps, do you want to say a few quick words of introduction just on the quarter thing and then we'll get started.
Roland Sackers - Qiagen N.V. - CFO, MD & Member of Management Board
Yes. First of all, thanks, Peter, for having us today, and thanks also for joining us. It's quite obvious that we are quite happy to be here. And again, I still recall -- I think it was now 2 years ago when we had to -- after first COVID, we had first physical meeting here.
Peter James Welford - Jefferies LLC, Research Division - Senior Equity Analyst & European Pharmaceuticals Analyst
4 years ago -- 3 years ago.
Roland Sackers - Qiagen N.V. - CFO, MD & Member of Management Board
Time goes quickly. And so
Qiagen NV at Jefferies London Healthcare Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers